Aurobindo Pharma commissions 4 manufacturing plants for PenicillinG, other products
Hyderabad Aurobindo Pharma Limited has commissioned four state-of-the-art manufacturing facilities for PenicillinG, 6-Amino Penicillanic Acid (6-APA), Injectable products and Granulation, through its wholly owned subsidiaries- Lyfius Pharma, Qule Pharma, Eugia Steriles, Auroactive Pharma.
Whereas the injectable plant has an annual production capacity of 285 millions of Vials/Ampoules and the Granulated products plant has 13,200 tonne annually.
Please refer to the table below for the full details –
| Sl. No. | Subsidiary name | Plant location | Product profile | Estimated Annual production capacity at full utilization | Addressable market |
| 1 | Lyfius Pharma Private Limited | Kakinada SEZ area, Thondangi Mandal, Kakinada District, Andhra Pradesh, India | Penicillin-G (Pen-G) | 15,000 MT | Captive use, Domestic supply and Exports |
| Glucose | 1,80,000 MT | ||||
| 2 | Qule Pharma Private Limited | Kakinada SEZ area, Thondangi Mandal, Kakinada District, Andhra Pradesh, India | 6- Amino Penicillanic Acid (6-APA) | 3,600 MT | |
| 3 | Eugia Steriles Private Limited | Tadi Village, Parawada Mandal, Anakapalli District, Andhra Pradesh, India | Vials / Ampoules | 285 Mn | Exports |
|
4 | Auroactive Pharma Private Limited | Sancham Village, Ranasthalam Mandal, Srikakulam District, Andhra Pradesh, India | Granulated products (Ready to Compress) | 13,200 MT | Captive use, Domestic supply and Exports |
"The business of the respective entities has commenced by undertaking commercial production of the products. Based on the purchase orders received, the respective companies have made commercial sale to its customers," the Company stated in a BSE filing.
The business’ revenues and profitability of the respective entities are expected to grow over a period of time.
Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company has 25 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company’s product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, AntiRetroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.
Read also: Aurobindo Pharma bags USFDA nod for Mometasone Furoate Monohydrate Nasal Spray
